Thermo Fisher Scientific announced its acquisition of Sanofi's manufacturing site in Ridgefield, New Jersey. This strategic purchase is aimed at expanding Thermo Fisher's U.S. manufacturing footprint and enhancing its capabilities to produce critical medicines.
The acquired site will be utilized to produce medicines for the French drugmaker Sanofi, strengthening the existing strategic partnership between the two companies. This move aligns with the growing demand for domestic drug production and supports a resilient U.S. healthcare supply chain.
This acquisition further bolsters Thermo Fisher's contract development and manufacturing organization (CDMO) services, allowing it to better serve pharmaceutical clients by increasing capacity and offering integrated solutions for drug development and production.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.